

1 **Clinical Validation of Automated and Rapid mariPOC SARS-CoV-2 Antigen** 2 **Test**

3 Juha M. Koskinen,^{1,2*} Petri Antikainen,¹ Kristina Hotakainen,^{3,4} Anu Haveri,⁵ Niina Ikonen,⁵
4 Carita Savolainen-Kopra,⁵ Kati Sundström,^{6,7} Janne O. Koskinen^a

5 ¹ArcDia International Ltd, Turku, Finland

6 ²Faculty of Medicine, University of Turku, Turku, Finland

7 ³Mehiläinen Oy, Helsinki, Finland

8 ⁴Department of Clinical Chemistry and Haematology, University of Helsinki, Helsinki, Finland

9 ⁵Finnish Institute for Health and Welfare, Helsinki, Finland

10 ⁶SataDiag, Pori, Finland

11 ⁷Department of Clinical Chemistry, Faculty of Medicine and Health Technology, Tampere
12 University, Tampere, Finland

13 *Address correspondence to Juha Koskinen, juha.koskinen@arcdia.com

14 JMK and PA contributed equally to the manuscript.

15 **Abstract** Novel SARS coronavirus causing COVID-19 was recognized in late 2019. Diagnostics
16 was quickly ramped up worldwide based on the detection of viral RNA. Based on the scientific
17 knowledge for pre-existing coronaviruses, it was expected that the RNA of this novel
18 coronavirus will be detected from symptomatic and at significant rates also from asymptomatic

19 individuals due to persistence of non-infectious RNA. To increase the efficacy of diagnostics,
20 surveillance, screening and pandemic control, rapid methods, such as antigen tests, are needed
21 for decentralized testing and to assess infectiousness. The objective was to validate the analytical
22 and clinical performance, and usability of a novel automated mariPOC SARS-CoV-2 test, which
23 is based on the detection of structural viral proteins using sophisticated optical laser technology.
24 Clinical performance of the test was evaluated against qRT-PCR with nasopharyngeal swab
25 specimens collected from patients suspected of acute SARS-CoV-2 infection. Sensitivity of the
26 mariPOC test was 100.0% (13/13) directly from swab specimens and 84.4% (38/45) from swab
27 specimens in undefined transport mediums. Specificity of the test was 100.0% (201/201). The
28 test's limit of detection was 2.7 TCID₅₀/test and had no cross-reactions with the tested respiratory
29 microbes. Our study shows that the mariPOC can detect infectious individuals already in 20
30 minutes with clinical sensitivity close to qRT-PCR. The test targets conserved epitopes of SARS-
31 CoV-2 nucleoprotein, making it robust against strain variations. The new test is a promising and
32 versatile tool for syndromic testing of symptomatic cases and for high capacity infection control
33 screening.

34 **Keywords** COVID-19, SARS-CoV-2, antigen detection, mariPOC, PCR, infectious, screening,
35 infection control, pandemic

36 **Introduction**

37 Emerging pandemic coronavirus (CoV) was recognized in Wuhan, China, in late 2019. The
38 virus, isolated from patients mentioned to be pneumonic, was quickly sequenced to share 79.6%
39 full length genome similarity with the Severe Acute Respiratory Syndrome virus (SARS-CoV-1)
40 and 91.2% similarity between its nucleocapsid (N) proteins (1). The novel SARS-CoV-2,

41 causing COVID-19, was identified to be circulating in horseshoe bats for decades similarly to
42 SARS-CoV-1 (2). Diagnostic nucleic acid amplification tests (NAAT), mostly quantitative real-
43 time polymerase chain reaction (qRT-PCR), were quickly developed worldwide, based on
44 protocol provided for World Health Organization (3). Diagnostic qRT-PCR capacities were
45 ramped up quickly in central laboratories because such tests are fast to develop for new targets.
46 Most often, the new qRT-PCR tests were adopted for clinical diagnostics with minimal
47 verification and validation against other diagnostic test methods.

48 For the seasonal coronaviruses, the interpretation of gene positivity in clinical specimens has
49 been challenging since the viral RNA is detected at similar rates and qRT-PCR cycle threshold
50 (Ct) values from symptomatic and asymptomatic individuals. The viral RNA is also co-detected
51 with genomes of other respiratory viruses (4-7). This is also the case for the SARS-CoV-2 (8, 9).
52 Moreover, recent scientific evidence indicates that qRT-PCR positivity has poor correlation for
53 assessment of SARS-CoV-2 infectiousness (10-16). Whereas, Pekosz et al. (2020) showed that
54 the detection of N-protein by an antigen test correlates with SARS-CoV-2 viral culture more
55 accurately than qRT-PCR (13). Already half a decade ago Inagaki et al. (2016) unequivocally
56 concluded for influenza that, “PCR...is not an appropriate method for indicating infectivity” and
57 “the antigen-detection test estimated the infectious period with comparable if not better accuracy
58 with culture” (17). In the case of COVID-19 diagnostics, the fact that viral RNA persistence can
59 be detected without viable virus for months, has been a known clinical challenge, as diagnostics
60 relied in the beginning of the pandemic solely on NAAT detection (18), the efficacy of which is
61 in ruling out positivity.

62 The expression of N-protein, which is the key pathogenicity factor of coronaviruses (19), is
63 essential for the coronavirus replication and transcription of the viral RNA (20, 21). Without the

64 accumulation of the N-protein, the coronaviral mRNA is degraded by the nonsense-mediated
65 decay (NMD) pathway of eukaryotic cells (19). Alexandersen et al. (2020) concluded that the
66 detection of RNA is not an indicator of actively replicating SARS-CoV-2. Their data suggests
67 that virion and subgenomic RNAs are stable in cellular double-membrane vesicles and, therefore,
68 can be detected long after the acute infection (22).

69 Shortly after viral exposure, viral concentration is low and qRT-PCR Ct values are high. When
70 the virus starts replication, it happens fast. In a cell model, extensive coronavirus RNA
71 transcription has occurred in 6 to 8 hours after the infection (23). In addition, NAATs being
72 prone for reporting clinically insignificant findings (analytically the detection may be correct,
73 there is viral RNA in the sample) they are prone to contaminations. A study of SARS-CoV-2
74 primer-probe sets from four major European suppliers found a significant level of contamination
75 from the reagents. False positives as low as qRT-PCR Ct 17 were obtained (24). Low levels of
76 SARS-CoV-2 RNA contamination has also been found from surfaces and air in rooms where
77 mildly ill individuals were isolated without notable viable virus (25, 26). It has also been shown
78 that environmental contamination may yield in positive test results in PCR among individuals
79 sampled in the same area where intranasal influenza vaccine dosing was done (27). These data
80 suggests that individuals having presence near symptomatic patients can be contaminated by
81 RNA without being infected with viable virus. Thus, methods detecting the viral RNA by
82 amplification are prone for clinically insignificant positive results, especially when significant
83 part of the population has been infected recently. The fact that a positive NAAT result is not a
84 reliable biomarker of active infection or COVID-19, is a true challenge for clinicians and
85 decision making for quarantine. It is not only that a missed necessary quarantine has health and

86 epidemic costs but also that a falsely imposed quarantine has social and financial consequences
87 (28).

88 The different performance requirements of diagnostic, surveillance and screening testing have
89 been recently discussed by Mina and Andersen (2020). There is a need for both super sensitive
90 PCR based tests and rapid and appropriately sensitive antigen tests to fight the COVID-19
91 pandemic (29). The use of the two methodologies should supplement one another in clinical
92 practice and pandemic fight.

93 In the present study, we analytically and clinically validated the performance of a novel 2nd
94 generation mariPOC SARS-CoV-2 test (ArcDia International Ltd, Finland), intended for rapid
95 and automated detection of viral acute phase proteins when there is a clinical suspicion of acute
96 COVID-19. Monoclonal antibodies of the test are designed to target a conserved epitope in the
97 N-protein, which is the most abundant protein in coronaviruses. We have previously shown that
98 the presence of coronavirus OC43 N-protein in the nasopharynx correlates with the respiratory
99 tract infection symptoms (30). It has been shown that clinical presentations of seasonal
100 coronavirus OC43 infections can be similar to those of coronaviruses that are considered as
101 severe viruses (SARS and MERS) (31).

102 The mariPOC is an automated platform for the rapid multianalyte testing of acute infectious
103 diseases. It is based on a separation-free two-photon excitation assay technique (32, 33).
104 Subsequently to nasopharyngeal sampling, the mariPOC test's operational steps are: combining
105 the swab with the sample buffer from a bottle-top dispenser, vortexing the sample tube to release
106 the sample from the swab (Fig. 1), followed by automated analysis and objective fluorescent
107 result read out. The analysis is performed by an automated analyzer with sophisticated

108 autoverification functions, and the result can be transferred automatically to the laboratory
109 information system or as anonymized epidemiological data (34) into mariCloud™ service. The
110 hands-on time is one minute per sample, and the analyzer works in continuous-feed and walk-
111 away mode. The mariPOC SARS-CoV-2 test is available as a single pathogen test and as part of
112 syndromic multianalyte tests covering, among others, influenza viruses. The throughput of one
113 mariPOC analyzer can be up to 300 single analyte tests or 100 multianalyte tests in 24 hours. The
114 results are reported in two phases, great majority of the infectious cases in twenty minutes and
115 very low positive and negative cases in 55 minutes or two hours, depending on the test
116 configuration.

117 **Materials and methods**

118 **Analytical sensitivity**

119 Nasopharyngeal swab specimens from asymptomatic individuals were pooled and suspended
120 into mariPOC RTI sample buffer into volume corresponding to 1.3 mL per swab. This pooled
121 clinical sample matrix (1.3 mL) was spiked with 75 µL of gamma-irradiation inactivated SARS-
122 CoV-2 cell lysate (stock 2.8×10^6 TCID₅₀/mL, USA-WA1/2020, NR-52287, lot 70035888, BEI
123 Resources, Manassas, VA, USA) in culture supernatant of different viral concentrations (50%
124 tissue culture infective dose, TCID₅₀). The samples were analyzed with the mariPOC SARS-
125 CoV-2 test following the manufacturer's instructions. Limit of Detection (LoD) was determined
126 as the lowest concentration giving at least 19 positives out of 20 replicates ($\geq 95\%$ positivity).

127 **Cross-reactivity**

128 Analytical specificity of the mariPOC SARS-CoV-2 test was studied by challenging the test
129 against relevant microbes commonly found in the nasal cavity (Online Resource). Briefly, the
130 microbe stocks were suspended in high concentration in the mariPOC RTI sample buffer and
131 analyzed with the mariPOC test.

132 **Clinical specificity**

133 Validation of the specificity of the mariPOC SARS-CoV-2 test was conducted in SataDiag
134 laboratory unit in Pori, Finland in February 2021 by one operator following the manufacturer's
135 instructions. In the study, 205 freshly sampled nasopharyngeal swab specimens were analyzed.
136 The samples were leftover samples from routine diagnostics with the 1st generation (launched
137 May 2020) mariPOC SARS-CoV-2 test. Samples positive in mariPOC were also analyzed with
138 the Xpert Xpress SARS-CoV-2 test (ref XPRSARS-COV2-10) detecting N2 and E-genes,
139 Cepheid, USA.

140 **Clinical sensitivity**

141 Sensitivity of the mariPOC SARS-CoV-2 test was validated with 58 frozen qRT-PCR positive
142 nasopharyngeal samples from two specimen cohorts.

143 Sample cohort 1

144 The first cohort consisted of 13 qRT-PCR positive nasopharyngeal swab samples collected from
145 patients (N=211) visiting primary healthcare COVID-19 drive-in stations of Mehiläinen Oy in
146 Helsinki capital area of Finland from March to April 2020. The qRT-PCR negative frozen
147 samples were not analyzed for this study because the test specificity was studied with fresh
148 samples as described above. The enrollment criteria were respiratory infection symptoms and

149 clinician's suspicion of COVID-19, the official criteria for COVID-19-testing in Finland, and at
150 the clinical study sites at the time of the study. The samples were taken with a flocked swab from
151 the nasopharynx (8 to 12 cm deep for adults and 4 to 8 cm deep for children) by rotating the
152 swab in nasopharyngeal cavity for 10 seconds. Two consecutive specimens were collected from
153 127 patients giving oral consent to participate in the study. The specimens were collected during
154 an internal laboratory method validation study, which does not require external ethical review
155 board permission and was not linked with recruitment or treatment of patients (35). The study
156 was approved by the responsible chief physician of Mehiläinen Oy, and by the responsible chief
157 physician and area manager of SataDiag laboratory division. The specimen for standard of care
158 testing was collected first. These specimens were analyzed after RNA extraction with Allplex™
159 2019-nCoV RT-PCR assay (Seegene Inc., Republic of Korea) at Seoul Clinical laboratories
160 (Republic of Korea). Allplex™ 2019-nCoV RT-PCR assay detects E, N and RdRP genes (36).
161 The second swab specimen was kept in a dry tube at +4 °C for a maximum of 8 hours and stored
162 frozen until analysis with the mariPOC SARS-CoV-2 test. For 84 patients, one nasopharyngeal
163 swab specimen was collected. These swabs were suspended into saline (0.5–1 mL) and analyzed
164 with Amplidiag COVID-19 qRT-PCR assay including RNA extraction (Mobidiag Ltd, Finland)
165 at Vita Laboratorio Ltd (Finland). Amplidiag COVID-19 qRT-PCR assay detects N and ORF1ab
166 genes (37). The leftover saline specimens were stored frozen until analysis with the mariPOC
167 SARS-CoV-2 test.

168 The dry swab specimens and leftover saline samples were analyzed retrospectively with the
169 mariPOC test by two operators following the manufacturer's instructions. Briefly, dry swabs
170 were suspended into 1.3 mL of the mariPOC RTI sample buffer and the leftover saline samples
171 (range 0.1–0.65 mL) were diluted with mariPOC RTI sample buffer to a final volume of 1.3 mL.

172 For this validation study, the samples were further diluted into the mariPOC RTI sample buffer
173 in one-to-one (1:1) ratio and analyzed with the mariPOC test. When a discrepant result between
174 the mariPOC and comparator RT-PCR was obtained, the swab samples taken for the mariPOC
175 were confirmatory tested at the Department of Clinical Microbiology, Turku University Hospital
176 (Finland) with an in-house reference qRT-PCR detecting E, N and RdRP genes (3).

177 Sample cohort 2

178 The second cohort consisted of forty five positive pseudonymized specimens with known qRT-
179 PCR Ct values (16 to 34) from the frozen nasopharyngeal swab specimen library of Finnish
180 Institute of Health and Welfare, Helsinki, Finland, in undefined transport mediums. The qRT-
181 PCR protocol was an in-house method based on the primers and probes by Corman et al. (2020)
182 (3). The cohort consisted mostly of symptomatic, but in part also of asymptomatic subjects,
183 while the detailed information for each subject was not available for this study. The specimens
184 were in either reddish (N=22) or colorless (N=23) solutions. The samples were diluted into the
185 mariPOC RTI sample buffer in one-to-one (1:1) ratio and analyzed with the mariPOC test. The
186 positivity rate of the mariPOC test was evaluated against different qRT-PCR Ct value categories
187 and then compared to published viral culture studies.

188 **Results**

189 **Analytical sensitivity**

190 LoD of the mariPOC SARS-CoV-2 test was 2.7 TCID₅₀/test in 20 µL reaction volume, at which
191 all twenty replicates gave a positive test result. Based on the certificate of analysis of the viral
192 preparation, the LoD equals to 1690 genome equivalents per test.

193 **Cross-reactivity**

194 The mariPOC test had no cross-reactions. The mariPOC test did not cross-react with seasonal
195 coronaviruses OC43, 229E, or NL63, but it detected the recombinant N-protein of SARS-CoV-1.
196 Detailed information is shown in supplemental material (Online Resource).

197 **Clinical specificity**

198 Specificity of the mariPOC test was 100.0% in the preliminary (200/200) and final (201/201)
199 result reporting phases. Three and two of the sample analyses were rejected by the
200 autoverification in the preliminary and final result reporting phases giving failure rates of 1.5%
201 and 1.0%, respectively. Two of the samples were positive in both the mariPOC test and routine
202 PCR test.

203 **Clinical sensitivity**

204 The sensitivity of the mariPOC SARS-CoV-2 test was 100.0% (13/13) in the preliminary and
205 final result reporting phases in sensitivity cohort 1, where the nasopharyngeal swab specimens
206 were suspended directly into the mariPOC sample buffer or first into saline (Table 1). Detailed
207 description of the positive samples are shown in supplemental material (Online Resource).
208 Prevalence of SARS-CoV-2 in the first sample cohort was 6%, which is well in alignment with
209 the prevalence during the study time in the geographical area (5%).

210 The sensitivity of the test in sensitivity cohort 2 was 73.3% (33/45) and 84.4% (38/45) in the
211 preliminary and final result reporting phases, respectively, when the nasopharyngeal swabs were
212 initially suspended in undefined transport mediums and further diluted with the mariPOC sample
213 buffer (Table 1). Based on 95% confidence interval, both cohorts had similar statistical reliability

214 (Table 1). Overall, 38 out of 45 samples were positive with the mariPOC in sensitivity cohort 2
215 (Fig. 2). The test showed 100% (31/31) positivity rate compared to qRT-PCR for Ct values ≤ 28
216 (Table 2). Above the Ct value 28, the positivity rate of the mariPOC declined as typical for an
217 antigen test, reaching 91.9% (34/37) with Ct values ≤ 30 .

218 **Discussion**

219 When setting up a diagnostic process or choosing a diagnostic method, one should carefully
220 consider, to start with, whether the disease, clinical condition and use case, require high
221 sensitivity for ruling out or high specificity for ruling in. There is a need for both in fighting the
222 COVID-19 pandemic. In general, analytically highly sensitive testing, such as PCR testing, is
223 good at ruling out a disease (e.g. keeping a ward clean) while highly specific testing, such as
224 antigen testing, is good at ruling in a disease (e.g. acute infection diagnostics and assessing
225 infectiousness). Because of rapidity and lesser logistic challenges compared to central lab testing,
226 antigen testing is particularly good in surveillance, field-testing, screening of masses, cohorting
227 of inpatients, acute disease diagnostics, and in assessing the infectiousness of individuals (13,
228 38). Especially when disease prevalence is low, clinical specificity of the screening and
229 diagnostic testing should be emphasized to keep unnecessary quarantines and economic damages
230 at minimum while still allowing sufficient enough infection control (29).

231 According to scientific data, to effectively prevent spread of the disease, pandemic control
232 should prioritize accessibility, frequency of testing, and rapid sample-to-answer time over test
233 sensitivity (37, 39, 40). Viral load and probability to infect others is highest just prior to onset of
234 symptoms and during the symptomatic phase (41).

235 We describe here analytical and clinical validation of mariPOC SARS-CoV-2 test sensitivity and
236 specificity. Determination of LoD was performed with gamma-irradiation inactivated viral
237 culture supernatant and showed that only less than three infectious units per test was needed for
238 positive test result. LoD was also determined as qRT-PCR Ct units using UV-inactivated virus
239 (Online Resource). The obtained Ct LoD was 33, which approaches the theoretical analytical
240 sensitivity of a typical PCR method with 5 µl cDNA volume and applying 95% confidence
241 interval. The maximum Ct values detected in clinical samples (Fig. 2 and Table 2.) were similar
242 to the determined Ct LoD.

243 Based on high identity (89.1%) between SARS-CoV-1 (Uniprot entry, P59595) and SARS-
244 CoV-2 (UniProt entry, P0DTC9) nucleocapsid protein sequences, and obtaining positive result
245 for purified SARS-CoV-1 nucleocapsid protein in cross-reactivity testing (Table S1 in the Online
246 Resource), it is highly likely that the mariPOC test detects also the SARS-CoV-1 virus itself.
247 Cross-reactions were not observed. A minor limitation of the study is that cross-reactivity for
248 MERS coronavirus and coronavirus HKU1 were assessed using purified protein and sequence
249 analysis (Online Resource) and not with clinical samples or cultured virus.

250 Our sensitivity validation cohort 1 showed 100% sensitivity. While the highest qRT-PCR Ct
251 obtained by the primary reference test in this cohort was 30.2, the cohort consisted of unselected
252 and consecutive samples collected from patients with clear symptoms. This might explain why
253 there were no samples with higher Ct values. The sensitivity cohort 2 showed 100% positivity
254 rate for the mariPOC below qRT-PCR Ct 28 (Table 2 and Fig. 2). This result was excellent
255 taking into account that the samples were unfavorable for the mariPOC platform with separation-
256 free fluorescent measurement. Colorful transport media are not recommended for mariPOC
257 testing since they elevate fluorescent signal levels (42) and unnecessarily dilute the samples,

258 which reduces sensitivity. The pooled sensitivity of sample cohorts 1 and 2 at qRT-PCR Ct \leq 30
259 was 94%, suggesting even higher sensitivity for mariPOC compared to what has been reported in
260 the literature for SARS-CoV-2 viral culture against qRT-PCR, as summarized in Table 2. In
261 addition, our results are in line with at least two other N-protein detecting tests that were
262 evaluated against RT-PCR and culture (43, 44). Several studies have shown that infectivity of
263 SARS-CoV-2 declines rapidly in samples showing qRT-PCR Ct above 25, and viable virus is
264 rarely isolated after 8 days from onset of the symptoms. The detection of sole viral RNA,
265 especially at low levels without the detectable level of viral N-protein or culture positivity, is a
266 questionable marker of acute infection and infectiousness (10-14, 16, 45-47).

267 The results suggest that the clinical sensitivity of the mariPOC test (84.4% in unfavorable sample
268 matrix to 100.0% when used according to manufacturer recommendations) is similar or even
269 better than that of at least some rapid RT-PCR tests (93.4%), (37) when symptomatic patients
270 suspected with acute COVID-19 infection are tested within the first five days of symptoms and
271 prevalence among tested samples is reasonable (6% in sensitivity study 1). Recommended
272 sample in the mariPOC test is native nasopharyngeal swab specimen suspended into 1.3 mL of
273 the RTI sample buffer. Other specimen types may yield in lower apparent sensitivity. In the
274 sensitivity cohort 1, suspending part of the swabs first into saline prior to the addition of
275 mariPOC RTI sample buffer followed by a further dilution into mariPOC RTI sample buffer by a
276 factor of two for the testing, diluted the specimens 4 to 20 times (2 to 4.3 PCR Ct units) more
277 than the recommended sample pretreatment. Additional dilution lowers the sensitivity compared
278 to the recommended protocol, and could have led to an underestimation of the test sensitivity.

279 Strengths of the sensitivity validation included that the specimens were collected in the early
280 phase of the COVID-19 pandemic in Finland that minimized the detection of RNA persistence
281 with the RT-PCR among the cohort population.

282 Limitations of the validation study were that the patient characteristics and the number of
283 symptomatic days before sampling were not available for the study. Freezing and thawing of the
284 positive samples prior to mariPOC testing and additional dilutions to the recommended protocol
285 were also limitations. However, if any, these could have had a negative effect on the mariPOC
286 test sensitivity and, hence, the study at least did not overestimate the sensitivity of the mariPOC
287 SARS-CoV-2 test.

288 **Conclusions**

289 The mariPOC SARS-CoV-2 test is an automated, highly specific and clinically accurate test with
290 rapid sample-to-answer time for individuals with clinical suspicion and in acute phase of an
291 infection. The closed tube test system and the design of operational steps minimize specimen
292 handling and possible exposure of user to infectious material. The multianalyte syndromic tests
293 help to differentiate between SARS-CoV-2 and other viruses, such as influenza. The single
294 analyte test provides high capacity of 300 samples a day at the point-of-sampling. Objective
295 result read-out and LIS connectability minimize manual work and human errors. Our study
296 together with other scientific data suggests that the mariPOC can detect majority of the cases
297 already in 20 minutes with sensitivity similar to a rapid PCR while maximum sensitivity is
298 achieved in 55 minutes. The positivity rate of mariPOC compared to qRT-PCR Ct values in
299 clinical samples is very high up to Ct 28-30, and samples at least up to Ct 33.24 (Fig. 2) or 35.78
300 (Online Resourcetable 2) can be detected depending on the PCR method and gene target. The

301 detection of conserved epitope in the N-protein of SARS coronaviruses with the mariPOC likely
302 provides accurate information about infectiousness similarly to other antigen tests and viral
303 culture and suggests ability to detect also emerging virus variants. Further studies using viral
304 culture as comparative method and follow-up of infectiousness of patients using antigen
305 detection are needed in order to optimize viral respiratory tract infection management.

306 **Supplemental material** Supplemental material is available as Online Resource.

307 Online Resource1, PDF file, 0.4 MB.

308 **Funding** ArcDia International Ltd contributed the study with the mariPOC test system and
309 consumables. The study was partly supported by Business Finland, the Finnish Funding Agency
310 for Innovation, under the project reference 35239/31/2020.

311 **Conflicts of interest** JMK, PA and JOK are employees at ArcDia International Ltd.

312 **Acknowledgements** We thank Vita laboratories Ltd and Seoul Clinical Laboratory for
313 performing RT-PCR analyses and Titta Lehtonen performing the mariPOC analyses in SataDiag.

314 **Compliance with ethical standards**

315 **Author contributions**

316 JMK and PA: Major contributions in the development of the mariPOC test, in scientific design
317 and execution of the studies, result analysis, scientific analysis, and writing of the manuscript.

318 KH: Major contributions in providing specimens for clinical validation, in scientific analysis and
319 revising the manuscript.

320 AH: Major contributions in providing specimens for clinical validation, in scientific analysis and
321 revising the manuscript.

322 NI and CS-K: Major contributions in scientific analysis, and revision of the manuscript.

323 KS: Major contributions in providing specimens for clinical validation, in scientific analysis and
324 revising the manuscript.

325 JOK: Major contributions in the development of the mariPOC test and in scientific design,
326 execution, and analysis of the results, and revision of the manuscript.

327 **References**

- 328 1. Zhou P, Yang X, Wang X, Hu B, Zhang L, Zhang W, Si H, Zhu Y, Li B, Huang C, Chen H, Chen J,
329 Luo Y, Guo H, Jiang R, Liu M, Chen Y, Shen X, Wang X, Zheng X, Zhao K, Chen Q, Deng F, Liu L,
330 Yan B, Zhan F, Wang Y, Xiao G, Shi Z (2020) A pneumonia outbreak associated with a new coronavirus
331 of probable bat origin. *Nature* 579:270-273. <https://doi.org/10.1038/s41586-020-2012-7>
- 332 2. Boni MF, Lemey P, Jiang X, Lam TT, Perry BW, Castoe TA, Rambaut A, Robertson DL (2020)
333 Evolutionary origins of the SARS-CoV-2 sarbecovirus lineage responsible for the COVID-19 pandemic.
334 *Nat Microbiol* 5:1408-1417. <https://doi.org/10.1038/s41564-020-0771-4>
- 335 3. Corman VM, Landt O, Kaiser M, Molenkamp R, Meijer A, Chu DK, Bleicker T, Brünink S, Schneider
336 J, Schmidt ML, Mulders DG, Haagmans BL, van der Veer B, van den Brink S, Wijsman L, Goderski G,
337 Romette J, Ellis J, Zambon M, Peiris M, Goossens H, Reusken C, Koopmans MP, Drosten C (2020)
338 Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR. *Euro Surveill* 25.
339 <https://dx.doi.org/10.2807%2F1560-7917.ES.2020.25.3.2000045>

- 340 4. Gaunt ER, Hardie A, Claas ECJ, Simmonds P, Templeton KE (2010) Epidemiology and clinical
341 presentations of the four human coronaviruses 229E, HKU1, NL63, and OC43 detected over 3 years
342 using a novel multiplex real-time PCR method. *J Clin Microbiol* 48:2940-2947.
343 <https://doi.org/10.1128/jcm.00636-10>
- 344 5. Prill MM, Iwane MK, Edwards KM, Williams JV, Weinberg GA, Staat MA, Willby MJ, Talbot HK,
345 Hall CB, Szilagyi PG, Griffin MR, Curns AT, Erdman DD (2012) Human coronavirus in young children
346 hospitalized for acute respiratory illness and asymptomatic controls. *Pediatr Infect Dis J* 31:235-240.
347 <https://doi.org/10.1097/inf.0b013e31823e07fe>
- 348 6. Rhedin S, Lindstrand A, Rotzén-Östlund M, Tolfvenstam T, Ohrmalm L, Rinder MR, Zwegberg-
349 Wirgart B, Örtqvist A, Henriques-Normark B, Broliden K, Naucler P (2014) Clinical utility of PCR for
350 common viruses in acute respiratory illness. *Pediatrics* 133:538. <https://doi.org/10.1542/peds.2013-3042>
- 351 7. Rhedin S, Lindstrand A, Hjelmgren A, Ryd-Rinder M, Öhrmalm L, Tolfvenstam T, Örtqvist Å,
352 Rotzén-Östlund M, Zwegberg-Wirgart B, Henriques-Normark B, Broliden K, Naucler P (2015)
353 Respiratory viruses associated with community-acquired pneumonia in children: matched case-control
354 study. *Thorax* 70:847-853. <https://doi.org/10.1136/thoraxjnl-2015-206933>
- 355 8. Chau NVV, Thanh Lam V, Thanh Dung N, Yen LM, Minh NNQ, Hung LM, Ngoc NM, Dung NT,
356 Man DNH, Nguyet LA, Nhat LTH, Nhu LNT, Ny NTH, Hong NTT, Kestelyn E, Dung NTP, Xuan TC,
357 Hien TT, Thanh Phong N, Tu TNH, Geskus RB, Thanh TT, Thanh Truong N, Binh NT, Thuong TC,
358 Thwaites G, Tan LV (2020) The natural history and transmission potential of asymptomatic SARS-CoV-
359 2 infection. *Clin Infect Dis* 71:2679-2687. <https://doi.org/10.1093/cid/ciaa711>
- 360 9. Kissler SM, Fauver JR, Mack C, Tai C, Shiue KY, Kalinich CC, Jednak S, Ott IM, Vogels CBF,
361 Wohlgenuth J, Weisberger J, DiFiori J, Anderson D, Mancell J, Ho DD, Grubaugh ND, Grad YH

- 362 (2020) Viral dynamics of SARS-CoV-2 infection and the predictive value of repeat testing. medRxiv.
363 <https://doi.org/10.1101/2020.10.21.20217042>
- 364 10. Arons MM, Hatfield KM, Reddy SC, Kimball A, James A, Jacobs JR, Taylor J, Spicer K, Bardossy
365 AC, Oakley LP, Tanwar S, Dyal JW, Harney J, Chisty Z, Bell JM, Methner M, Paul P, Carlson CM,
366 McLaughlin HP, Thornburg N, Tong S, Tamin A, Tao Y, Uehara A, Harcourt J, Clark S, Brostrom-Smith
367 C, Page LC, Kay M, Lewis J, Montgomery P, Stone ND, Clark TA, Honein MA, Duchin JS, Jernigan JA
368 (2020) Presymptomatic SARS-CoV-2 Infections and Transmission in a Skilled Nursing Facility. N Engl J
369 Med 382:2081-2090. <https://doi.org/10.1056/nejmoa2008457>
- 370 11. Bullard J, Dust K, Funk D, Strong JE, Alexander D, Garnett L, Boodman C, Bello A, Hedley A,
371 Schiffman Z, Doan K, Bastien N, Li Y, Van Caesele PG, Poliquin G (2020) Predicting infectious SARS-
372 CoV-2 from diagnostic samples. Clin Infect Dis 71:2663–2666. <https://doi.org/10.1093/cid/ciaa638>
- 373 12. La Scola B, Le Bideau M, Andreani J, Hoang VT, Grimaldier C, Colson P, Gautret P, Raoult D
374 (2020) Viral RNA load as determined by cell culture as a management tool for discharge of SARS-CoV-2
375 patients from infectious disease wards. Eur J Clin Microbiol Infect Dis 39:1059-1061.
376 <https://doi.org/10.1007/s10096-020-03913-9>
- 377 13. Pekosz A, Cooper CK, Parvu V, Li M, Andrews JC, Manabe YC, Kodsi S, Leitch J, Gary DS, Roger-
378 Dalbert C (2020) Antigen-based testing but not real-time PCR correlates with SARS-CoV-2 virus culture.
379 Clin Infect Dis:ciaa1706. <https://doi.org/10.1093/cid/ciaa1706>
- 380 14. Singanayagam A, Patel M, Charlett A, Lopez Bernal J, Saliba V, Ellis J, Ladhani S, Zambon M,
381 Gopal R (2020) Duration of infectiousness and correlation with RT-PCR cycle threshold values in cases
382 of COVID-19, England, January to May 2020. Euro Surveill 25. [https://doi.org/10.2807/1560-
383 7917.es.2020.25.32.2001483](https://doi.org/10.2807/1560-7917.es.2020.25.32.2001483)

- 384 15. Cao S, Gan Y, Wang C, Bachmann M, Wei S, Gong J, Huang Y, Wang T, Li L, Lu K, Jiang H, Gong
385 Y, Xu H, Shen X, Tian Q, Lv C, Song F, Yin X, Lu Z (2020) Post-lockdown SARS-CoV-2 nucleic acid
386 screening in nearly ten million residents of Wuhan, China. *Nature Communications* 11:1-7.
387 <https://doi.org/10.1038/s41467-020-19802-w>
- 388 16. Jaafar R, Aherfi S, Wurtz N, Grimaldier C, Van Hoang T, Colson P, Raoult D, La Scola B (2020)
389 Correlation Between 3790 Quantitative Polymerase Chain Reaction–Positives Samples and Positive Cell
390 Cultures, Including 1941 Severe Acute Respiratory Syndrome Coronavirus 2 Isolates. *Clinical Infectious*
391 *Diseases*. <https://doi.org/10.1093/cid/ciaa1491>
- 392 17. Inagaki K, Song M, Crumpton J, DeBeauchamp J, Jeevan T, Tuomanen EI, Webby RJ, Hakim H
393 (2016) Correlation Between the Interval of Influenza Virus Infectivity and Results of Diagnostic Assays
394 in a Ferret Model. *J Infect Dis* 213:407-410. <https://doi.org/10.1093/infdis/jiv331>
- 395 18. Pollock AM, Lancaster J (2020) Asymptomatic transmission of covid-19. *BMJ* 371:m4851.
396 <http://dx.doi.org/10.1136/bmj.m4851>
- 397 19. Wada M, Lokugamage KG, Nakagawa K, Narayanan K, Makino S (2018) Interplay between
398 coronavirus, a cytoplasmic RNA virus, and nonsense-mediated mRNA decay pathway. *Proc Natl Acad*
399 *Sci U S A* 115:E10157-E10166. <https://doi.org/10.1073/pnas.1811675115>
- 400 20. Almazán F, Galán C, Enjuanes L (2004) The nucleoprotein is required for efficient coronavirus
401 genome replication. *J Virol* 78:12683-12688. <https://doi.org/10.1128/jvi.78.22.12683-12688.2004>
- 402 21. Zúñiga S, Cruz JLG, Sola I, Mateos-Gómez PA, Palacio L, Enjuanes L (2010) Coronavirus
403 nucleocapsid protein facilitates template switching and is required for efficient transcription. *J Virol*
404 84:2169-2175. <https://doi.org/10.1128/jvi.02011-09>

- 405 22. Alexandersen S, Chamings A, Bhatta TR (2020) SARS-CoV-2 genomic and subgenomic RNAs in
406 diagnostic samples are not an indicator of active replication. Nat Commun 11:6059.
407 <https://doi.org/10.1038/s41467-020-19883-7>
- 408 23. Hofmann MA, Sethna PB, Brian DA (1990) Bovine coronavirus mRNA replication continues
409 throughout persistent infection in cell culture. J Virol 64:4108-4114.
410 <https://doi.org/10.1128/jvi.64.9.4108-4114.1990>
- 411 24. Wernike K, Keller M, Conraths FJ, Mettenleiter TC, Groschup MH, Beer M (2020) Pitfalls in SARS-
412 CoV-2 PCR diagnostics. Transbound Emerg Dis. <https://doi.org/10.1111/tbed.13684>
- 413 25. Santarpia JL, Rivera DN, Herrera VL, Morwitzer MJ, Creager HM, Santarpia GW, Crown KK, Brett-
414 Major DM, Schnaubelt ER, Broadhurst MJ, Lawler JV, Reid SP, Lowe JJ (2020) Aerosol and surface
415 contamination of SARS-CoV-2 observed in quarantine and isolation care. Sci Rep 10:12732.
416 <https://doi.org/10.1038/s41598-020-69286-3>
- 417 26. Zhou J, Otter JA, Price JR, Cimpeanu C, Garcia DM, Kinross J, Boshier PR, Mason S, Bolt F,
418 Holmes AH, Barclay WS (2020) Investigating SARS-CoV-2 surface and air contamination in an acute
419 healthcare setting during the peak of the COVID-19 pandemic in London. Clin Infect Dis.
420 <https://doi.org/10.1093/cid/ciaa905>
- 421 27. Curran T, McCaughey C, Ellis J, Mitchell SJ, Feeney SA, Watt AP, Mitchell F, Fairley D, Crawford
422 L, McKenna J, Coyle PV (2012) False-positive PCR results linked to administration of seasonal influenza
423 vaccine. J Med Microbiol 61:332-338. <https://doi.org/10.1099/jmm.0.036178-0>
- 424 28. Surkova E, Nikolayevskyy V, Drobniowski F (2020) False-positive COVID-19 results: hidden
425 problems and costs. The lancet respiratory medicine 8:1167-1168. [http://dx.doi.org/10.1016/S2213-](http://dx.doi.org/10.1016/S2213-2600(20)30453-7)
426 [2600\(20\)30453-7](http://dx.doi.org/10.1016/S2213-2600(20)30453-7)

- 427 29. Mina MJ, Andersen KG (2020) COVID-19 testing: One size does not fit all. *Science* 371:126-127.
428 <https://doi.org/10.1126/science.abe9187>
- 429 30. Bruning AHL, Aatola H, Toivola H, Ikonen N, Savolainen-Kopra C, Blomqvist S, Pajkrt D, Wolthers
430 KC, Koskinen JO (2018) Rapid detection and monitoring of human coronavirus infections. *New*
431 *Microbes New Infect* 24:52-55. <https://doi.org/10.1016/j.nmni.2018.04.007>
- 432 31. Vandroux D, Allou N, Jabot J, Li Pat Yuen G, Brottet E, Roquebert B, Martinet O (2018) Intensive
433 care admission for Coronavirus OC43 respiratory tract infections. *Med Mal Infect* 48:141-144.
434 <https://doi.org/10.1016/j.medmal.2018.01.001>
- 435 32. Hänninen P, Soini A, Meltola N, Soini J, Soukka J, Soini E (2000) A new microvolume technique for
436 bioaffinity assays using two-photon excitation. *Nat Biotechnol* 18:548-550. <https://doi.org/10.1038/75421>
- 437 33. Koskinen JO, Vainionpää R, Meltola NJ, Soukka J, Hänninen PE, Soini AE (2007) Rapid method for
438 detection of influenza a and B virus antigens by use of a two-photon excitation assay technique and dry-
439 chemistry reagents. *J Clin Microbiol* 45:3581-3588. <https://doi.org/10.1128/JCM.00128-07>
- 440 34. Gunell M, Antikainen P, Porjo N, Irjala K, Vakkila J, Hotakainen K, Kaukoranta SS, Hirvonen JJ,
441 Saha K, Manninen R, Forsblom B, Rantakokko-Jalava K, Peltola V, Koskinen JO, Huovinen P (2016)
442 Comprehensive real-time epidemiological data from respiratory infections in Finland between 2010 and
443 2014 obtained from an automated and multianalyte mariPOC® respiratory pathogen test. *Eur J Clin*
444 *Microbiol Infect Dis* 35:405-413. <https://doi.org/10.1007/s10096-015-2553-0>
- 445 35. Vakkila J, Koskinen JO, Brandt A, Muotiala A, Liukko V, Soittu S, Meriluoto S, Vesalainen M,
446 Huovinen P, Irjala K (2015) Detection of Group A Streptococcus from Pharyngeal Swab Samples by
447 Bacterial Culture Is Challenged by a Novel mariPOC Point-of-Care Test. *Journal of Clinical*
448 *Microbiology* 53:2079-2083. <https://doi.org/10.1128/jcm.00018-15>

- 449 36. Liotti FM, Menchinelli G, Marchetti S, Morandotti GA, Sanguinetti M, Posteraro B, Cattani P (2020)
450 Evaluation of three commercial assays for SARS-CoV-2 molecular detection in upper respiratory tract
451 samples. *European Journal of Clinical Microbiology & Infectious Diseases: Official Publication of the*
452 *European Society of Clinical Microbiology* 40:269-277. <https://doi.org/10.1007/s10096-020-04025-0>
- 453 37. Jokela P, Jääskeläinen AE, Jarva H, Holma T, Ahava MJ, Mannonen L, Lappalainen M, Kurkela S,
454 Loginov R (2020) SARS-CoV-2 sample-to-answer nucleic acid testing in a tertiary care emergency
455 department: evaluation and utility. *J Clin Virol* 131:104614. <https://doi.org/10.1016/j.jcv.2020.104614>
- 456 38. Guglielmi G (2020) Fast coronavirus tests: what they can and can't do. *Nature* 585:496-498.
457 <https://doi.org/10.1038/d41586-020-02661-2>
- 458 39. Larremore DB, Wilder B, Lester E, Shehata S, Burke JM, Hay JA, Tambe M, Mina MJ, Parker R
459 (2020) Test sensitivity is secondary to frequency and turnaround time for COVID-19 screening. *Sci Adv*
460 7:eabd5393. <https://doi.org/10.1126/sciadv.abd5393>
- 461 40. Mina MJ, Parker R, Larremore DB (2020) Rethinking Covid-19 Test Sensitivity - A Strategy for
462 Containment. *N Engl J Med* 383:e120. <https://doi.org/10.1056/nejmp2025631>
- 463 41. He X, Lau EHY, Wu P, Deng X, Wang J, Hao X, Lau YC, Wong JY, Guan Y, Tan X, Mo X, Chen Y,
464 Liao B, Chen W, Hu F, Zhang Q, Zhong M, Wu Y, Zhao L, Zhang F, Cowling BJ, Li F, Leung GM
465 (2020) Temporal dynamics in viral shedding and transmissibility of COVID-19. *Nat Med* 26:672-675.
466 <https://doi.org/10.1038/s41591-020-0869-5>
- 467 42. Koskinen JM, Soukka JM, Meltola NJ, Koskinen JO (2018) Microbial identification from feces and
468 urine in one step by two-photon excitation assay technique. *Journal of Immunological Methods* 460:113-
469 118. <https://doi.org/10.1016/j.jim.2018.06.017>

- 470 43. Albert E, Torres I, Bueno F, Huntley D, Molla E, Fernández-Fuentes MÁ, Martínez M, Poujois S,
471 Forqué L, Valdivia A, Solano de la Asunción, Carlos, Ferrer J, Colomina J, Navarro D (2020) Field
472 evaluation of a rapid antigen test (Panbio™ COVID-19 Ag Rapid Test Device) for COVID-19 diagnosis
473 in primary healthcare centres. *Clin Microbiol Infect.* <https://doi.org/10.1016/j.cmi.2020.11.004>
- 474 44. Rusanen J, Kareinen L, Szirovicza L, Uğurlu H, Levanov L, Jääskeläinen A, Ahava M, Kurkela S,
475 Saksela K, Hedman K, Vapalahti O, Hepojoki J (2020) A generic, scalable, and rapid TR-FRET –based
476 assay for SARS-CoV-2 antigen detection. *medRxiv.* <https://doi.org/10.1101/2020.12.07.20245167>
- 477 45. Wölfel R, Corman VM, Guggemos W, Seilmaier M, Zange S, Müller MA, Niemeyer D, Jones TC,
478 Vollmar P, Rothe C, Hoelscher M, Bleicker T, Brünink S, Schneider J, Ehmann R, Zwirgmaier K,
479 Drosten C, Wendtner C (2020) Virological assessment of hospitalized patients with COVID-2019. *Nature*
480 581:465-469. <https://doi.org/10.1038/s41586-020-2196-x>
- 481 46. Sohn Y, Jeong SJ, Chung WS, Hyun JH, Baek YJ, Cho Y, Kim JH, Ahn JY, Choi JY, Yeom J (2020)
482 Assessing Viral Shedding and Infectivity of Asymptomatic or Mildly Symptomatic Patients with COVID-
483 19 in a Later Phase. *J Clin Med* 9:2924. <https://doi.org/10.3390/jcm9092924>
- 484 47. Basile K, McPhie K, Carter I, Alderson S, Rahman H, Donovan L, Kumar S, Tran T, Ko D, Sivaruban
485 T, Ngo C, Toi C, O'Sullivan MV, Sintchenko V, Chen SC-, Maddocks S, Dwyer DE, Kok J (2020) Cell-
486 based culture of SARS-CoV-2 informs infectivity and safe de-isolation assessments during COVID-19.
487 *Clin Infect Dis:ciaa1579.* <https://doi.org/10.1093/cid/ciaa1579>

488 **Table 1** Sensitivity of the mariPOC SARS-CoV-2 test when compared with the qRT-PCR methods.


Sample cohort	mariPOC result phase	No. of specimens		Sensitivity (%) (95% CI)
		TP	FN	
1	Final	13	0	100.0 (75.3– 100.0)
	Preliminary	13	0	100.0 (75.3– 100.0)
2	Final	38	7	84.4 (70.5–93.5)
	Preliminary	33	12	73.3 (58.1–85.4)

489 TP = true positive, FN = false negative, CI = confidence interval (exact Clopper-Pearson method).

490 **Table 2 Comparison of** cumulative positivity rates of viral culture (four studies) and mariPOC
 491 (sensitivity sample cohort 2) to qRT-PCR below different Ct categories. (10, 12, 14, 47)


	Arons	La Scola	Singanayagam	Basile	mariPOC	
					Preliminary	Final
Ct < 25	87%	83%	85%	89%	100.0% (20/20)	100.0% (20/20)
Ct < 28	77%	77%	NA	86%	90.3% (28/31)	100.0% (31/31)
Ct < 30	67%	75%	74%	82%	83.8% (31/37)	91.9% (34/37)
Overall	62%	68%	30%	NA	73.3% (33/45)	84.4% (38/45)

492 NA = not applicable




- 493 ① Add the specimen ② Add the buffer ③ Vortex


494 **Fig. 1** Sample pretreatment in the mariPOC SARS-CoV-2 test before placing the sample tube into the
 495 analyzer for automated analysis and subsequent test result read out objectively as positive or negative.




497 **Fig. 2** Ct values of qRT-PCR for mariPOC test positive (green dots) and negative (red dots) samples in
 498 the validation sample cohort 2. Dashed line is at Ct 33.24, which was the lowest detected Ct.
 499



1 Add the specimen



2 Add the buffer



3 Vortex

